The future of Alzheimer's biomarker testing

This video explores the latest advances in detecting central nervous system (CNS) biomarkers in blood—a critical step forward in understanding and diagnosing neurological diseases. The presentation begins by addressing the core challenges of measuring CNS biomarkers in blood, including their low concentrations and the influence of peripheral sources. It also highlights the role of blood-brain barrier dysfunction in allowing CNS proteins to enter the bloodstream, and discusses both the limitations and benefits of using blood as a testing matrix. The use of immunoprecipitation is presented as a powerful method to enhance the detection of these biomarkers, supported by recent study data and findings.

The discussion then turns to brain-derived tau (BD-Tau), a major breakthrough in blood-based testing for Alzheimer’s disease. Viewers will gain insight into the biology of BD-Tau, how it differs from other tau isoforms, and why it offers greater specificity for Alzheimer’s pathology. Data from recent studies are shared to demonstrate the promise of BD-Tau in improving early diagnosis and monitoring.

Finally, the video introduces Tecan’s innovative solutions that are helping researchers advance their CNS studies. From sensitive detection to automated workflows, Tecan’s technologies are designed to keep your research at the forefront of biomarker science.